SAN JOSE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral ...
Welcome to the Rani Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are a in a listen-only mode. Following ...
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit ...
Talat Imran: Thank you. I’m delighted to share the highlights of Rani Therapeutics’ strong performance in 2023 during which the company achieved numerous milestones in the development of its pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results